G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

CYP2C9

Cytochrome P450 Family 2 Subfamily C Member 9

CHR 10
10q23.33

Overview

The CYP2C9 gene accounts for nearly 20 percent of all cytochrome P450 enzyme volume in the human liver. It handles the oxidative breakdown of over-the-counter NSAID painkillers (ibuprofen, naproxen, diclofenac, celecoxib), the potent active enantiomer S-warfarin, antidiabetic sulfonylureas, anti-seizure drug phenytoin, and the multiple sclerosis therapy siponimod.

Roughly one-third of Europeans carry reduced-function *2 or *3 variants—making CYP2C9 one of the most frequent actionable targets in everyday medication safety.

📍 Position
10q23.33 (Chromosome 10)
🏷️ Category
Detoxification & Pharmacogenetics
🧪 Function
Phase I Hepatic Drug Enzyme
📊 Influence
NSAID, warfarin & phenytoin clearance

Function of CYP2C9

CPIC pharmacogenetic scoring assigns 1.0 to normal *1 alleles, 0.5 to *2, and ~0.0–0.25 to *3. Activity scores below 1.5 slow active-drug breakdown, prolonging blood residence time.

Key Aspects:

💊 Painkillers & Stomach Lining

Poor metabolizers (*3/*3 or *2/*3) accumulate high ibuprofen, meloxicam, or celecoxib blood levels over repeated days—elevating GI irritation, ulcer, and kidney risk.

🩸 Mandatory Pre-Treatment Check

Before prescribing siponimod (Mayzent), CYP2C9 genotyping is clinically mandatory: *3/*3 homozygotes are strictly contraindicated due to cardiac conduction risk.

💡 Double Coagulation Team: S-warfarin depends on CYP2C9 clearance while vitamin K recycling depends on VKORC1—clinicians combine both markers for precise starting doses.

🧬 Genetic Variants (SNPs)

Two coding SNPs identify the dominant European CYP2C9 *2 and *3 alleles:

rs1799853
10:94942290
Normal (*1)

C
/
Moderate (*2)

T
CYP2C9*2 (Arg144Cys)
Reduces cytochrome reductase interaction, lowering catalytic activity (~50% per allele) for warfarin and common NSAIDs.
*2 allele frequency:
~12% (Europe)
rs1057910
10:94981296
Normal (*1)

A
/
Severe (*3)

C
CYP2C9*3 (Ile359Leu)
Distorts the substrate binding pocket, slashing clearance by up to ~85–90%; requires marked warfarin and phenytoin reductions.
*3 allele frequency:
~7% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Lowest Effective NSAID Dose: Poor metabolizers benefit from starting at 25–50% standard celecoxib/meloxicam/ibuprofen doses or using acetaminophen when appropriate.
  • Pre-Warfarin / Siponimod Testing: Provide CYP2C9 status to prescribers prior to anticoagulation or MS therapy initiation.
  • Monitor Blood Glucose on Sulfonylureas: Slow clearance of glipizide or glimepiride can trigger prolonged hypoglycemia.

⚠️ Clinical Notes & Risks

  • GI & Renal NSAID Toxicity: Multi-day standard NSAID dosing in activity score 0–1 patients raises GI bleed risk.
  • Supratherapeutic Warfarin INR: *2/*3 and *3/*3 genotypes reach dangerously thin blood faster on standard loading schedules.
  • Phenytoin Ataxia: Accumulation produces dizziness, nystagmus, and slurred speech.
🩺 Medical Disclaimer: Genetic test results for CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #601130 (Cytochrome P450, Subfamily IIC, Polypeptide 9)
  • dbSNP: rs1799853 (*2), rs1057910 (*3)
  • CPIC Guidelines: CYP2C9 and NSAIDs, Warfarin, and Phenytoin
  • PharmGKB: Clinical Annotations Level 1A for CYP2C9

Last Update: November 2026

Related Research Guides for CYP2C9

Related Genes in Detoxification